Methamphetamine pharmacotherapy options: existing evidence and new directions

An estimated 7.4 million people worldwide are dependent on methamphetamine. Increasing harm is apparent in many countries, including the United Kingdom. Methamphetamine dependence is a chronic relapsing condition that is associated with elevated risk of psychosis, cardiovascular events, suicide and homicide, accidental injury and death. There are no pharmacotherapies currently approved to treat methamphetamine dependence, with treatment reliant on psychosocial approaches. This talk will cover the current evidence for methamphetamine pharmacotherapies, discuss the challenges with their application, and opportunities for new developments in the field.

Speakers

Professor Rebecca McKetin, National Drug and Alcohol Research Centre, University of New South Wales

Availability

This webinar is part of the Congress webinar 2025 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2025 package can be purchased below.